Pharmacy Residency Program in Oncology
SKCCC houses specialized training programs for PharmDs including a year-long Oncology Residency for PGY2s. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care in academic or other specialized settings.
The program includes core experiences including in inpatient medical oncology, hematologic malignancies, multiple myeloma, lymphoma and bone marrow transplantation as well as ambulatory clinical experiences across solid and hematologic malignancies, rotations in pain and palliative care as well as longitudinal oncology practice administration. Trainees also have the opportunity to choose electives including in pediatric oncology, benign hematology, oncology critical care as well as immunocompromised infectious disease.
Investigational Drugs and Research Pharmacy Residency Program
This Investigational Drugs and Research Residency Program focuses on training in investigational drug use and regulatory compliance. The pharmacy residency program offers the opportunity to develop clinical, analytical, teaching, and leadership skills required to support clinical trials research. The program encompasses clinical research, medication safety, leadership, regulatory compliance, and quality assurance and is designed to develop expert skills in pharmacists’ provision of care for patients enrolled in clinical trials.
The residency program takes place over two years, with the PGY1 year building a clinical pharmacy foundation that may be applied within the PGY2 year. Each resident has the opportunity to work in oncology-related fields by staffing in the Weinberg Oncology Pharmacy within The Johns Hopkins Hospital, as well as participating in oncology rotations such as Oncology Investigational Drug Services (IDS), Clinical Pharmacology/Drug Development with Dr. Michelle Rudek (hyperlink), and other patient focused oncology rotations (Hematologic Malignancies, Bone Marrow Transplant, Medical Oncology, and more).
The inaugural curriculum has been accredited and widely disseminated beyond SKCCC (Wascher et al. Am J Health-Syst Pharm 2019), and since the its launch at The Johns Hopkins Hospital in 2017, three additional Investigational Drugs and Research Pharmacy Residency Programs started at University of Michigan, Yale New Haven, and the National Institutes of Health.